HLA: A pharmacogenomics success story

Pharmacogenomics

Volumn 11, Issue 3, 2010, Pages 277-281

  Becquemont, Laurent ^a,b  

^a Centre de Recherche Clinique Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; CARBAMAZEPINE; CLOZAPINE; FLUCLOXACILLIN; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN E ANTIBODY; LAMOTRIGINE; NEVIRAPINE; OXICAM DERIVATIVE; PHENYTOIN; SULFAMETHOXAZOLE; XIMELAGATRAN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGEN PRESENTING CELL; DELAYED HYPERSENSITIVITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; EDITORIAL; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LYMPHOCYTOTOXICITY; NEUTROPENIA; PHARMACOGENOMICS; PROTEIN EXPRESSION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; URTICARIA;

ALLELES; DRUG TOXICITY; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; MODELS, IMMUNOLOGICAL; PHARMACOGENETICS; RISK FACTORS;

EID: 77949619309     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.38     Document Type: Editorial

References (33)

1. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-ana lysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
2. Wysowski D, Swartz L: Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch. Intern. Med. 165, 1363-1369 (2005).
3. Pichler WJ: Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139(8), 683-693 (2003).
4. Matzinger P: Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
5. Torres MJ, Mayorga C, Blanca M: Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J. Investig. Allergol. Clin. Immunol. 19(2), 80-90 (2009).
6. Dedeoglu F: Drug-induced autoimmunity. Curr. Opin. Rheumatol. 21(5), 547-551 (2009).
7. Hetherington S, Hughes A, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
8. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002).
9. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
10. Higgs J, Gambhir N, Ramsden SC, Poulton K, Newman WG: Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. Genet. Test Mol. Biomarkers 14(1), 121-125 (2009).
11. Watson ME, Patel LG, Ha B, Wannamaker P, Cuffe R, Shaefer M: A study of HIV provider attitudes toward HLA-B 5701 testing in the United States. AIDS Patient Care STDS 23(11), 957-963 (2009).
12. Young B, Squires K, Patel P et al.: First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 22(13), 1673-1675 (2008).
13. Chung W, Hung S, Hong H et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
14. Locharernkul C, Loplumlert J, Limotai C et al.: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008).
15. Holdsworth R, Hurley CK, Marsh SG et al.: The HLA dictionary 2008: a summary of HLA-A,-B,-C,-DRB1/3/4/5, and-DQB1 alleles and their association with serologically defned HLA-A,-B,-C,-DR, and-DQ antigens. Tissue Antigens 73(2), 95-170 (2009).
16. Horton R, Wilming L, Rand V et al.: Gene map of the extended major histocompatibility complex Nat. Rev. Genet. 5, 889-899 (2004).
17. Nelson M, Bacanu S-A, Mosteller M et al.: Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 9(1), 23-33 (2009).
18. Daly A, Donaldson P, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41, 816-819 (2009).
19. Becquemont L: Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10(6), 961-969 (2009).
20. Hughes DA, Vilar FJ, Ward CC, Alfrevic A, Park BK, Pirmohamed M: Cost-effectiveness ana lysis of HLA-B*5 701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14(6), 335-342 (2004).
21. Lonjou C, Thomas L, Borot N et al.: A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006).
22. Hung SI, Chung WH, Jee SH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297-306 (2006).
23. Hung S, Chung W, Liou L et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
24. Donaldson P, Bhatnagar P, Graham J et al.: Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor. Hepatology 48(Suppl. 4), A396-A397 (2008).
25. Martin A, Nolan D, James I et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DR B1*0101 and abrogated by low CD4 T-cell counts. AIDS 19, 97-99 (2005).
26. Littera R, Carcassi C, Masala A et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20, 1624-1626 (2006).
27. Kindmark A, Jawaid A, Harbron C et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008).
28. Gueant-Rodriguez RM, Gueant JL, Viola M, Tramoy D, Gaeta F, Romano A: Association of tumor necrosis factor-a-308G>A polymorphism with IGE-mediated allergy to betalactams in an Italian population. Pharmacogenomics J. 8(2), 162-168 (2008).
29. Romano A, De Santis A, Romito A et al.: Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol. 80(5), 433-437 (1998).
30. O'Donohue J, Oien KA, Donaldson P et al.: Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47(5), 717-720 (2000).
31. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R: Clozapine-induced agranulocytosis in schizophrenic Caucasians: confrming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 7(5), 325-332 (2007).
32. Lonjou C, Borot N, Sekula P et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to fve high-risk drugs. Pharmacogenet. Genomics 18(2), 99-107 (2008).
33. Kim SH, Choi JH, Lee KW et al.: The human leucocyte antigen- DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin. Exp. Allergy 35(3), 339-344 (2005).